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Abstract: 
This thesis summarises the author’s lifelong work to improve outcomes for patients with 
musculoskeletal tumours. It starts with analysing diagnostic features and steps that could 
be taken to improve the time to diagnosis of these rare tumours. It continues with a 
number of basic science projects which the author has either carried out or collaborated 
with. Benign bone tumours are common in children and are discussed. The author has 
probably one of the largest personal experiences of treating primary malignant bone and 
soft tissue tumours and this is evidenced by the papers on osteosarcoma, 
chondrosarcoma, Ewing’s sarcoma and soft tissue sarcoma. The indications for and 
outcomes of major ablative amputations are outlined followed by an extensive review of 
the outcomes of limb salvage surgery with endoprostheses and other techniques. The 
role of this type of surgery in metastatic disease is put in context. Finally the importance 
of follow up and guidelines is considered. The thesis represents an analysis of the huge 
improvements that have taken place in the past 25 years in musculoskeletal oncology but 
also reveals the many still unanswered questions in this evolving field.   
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Background 
In 1976 I qualified as a doctor and had the privilege of working as House Surgeon at the 
Middlesex Hospital in London to Rodney Sweetnam (later Sir Rodney, PRCS). At the time 
he was the secretary of the MRC Bone Tumour working party and was recognised as one 
of the country’s leading surgeons dealing with bone tumours. As a result of this I saw a lot 
of patients with bone tumours, almost all of whom were treated by amputation, despite 
which, most succumbed rapidly to metastatic disease.  In 1980, with a FRCS qualification, 
I was appointed as a Registrar to the Royal Orthopaedic Hospital in Birmingham, where I 
was sent to work with Rodney Sneath who ‘did’ the bone tumours.  
In four short years the management of bone sarcomas had changed dramatically from 
amputation and almost certain death to the use of chemotherapy, limb salvage and a 
chance of cure. The limb salvage operations were made possible because of Rodney 
Sneath’s strong links with Prof John Scales of the Institute of Bioengineering who 
manufactured custom made prostheses for these patients. ‘Prof’ would deliver them 
himself to the hospital and would regularly attend clinics and operating lists to evaluate 
the success of the implants. He was an inspirational character and realising my 
enthusiasm for the subject he suggested that I might like to ‘record some of the outcomes 
for posterity’.  
In 1986 I took a year out of the training program to establish a database to record patient, 
tumour, treatment  and outcome data for patients referred to the Unit. This database was 
originally written in Informix but was later rewritten in SQL. This proved too cumbersome 
and for many years Filemaker Pro was used as the basis for the database. In 2005 this was 
replaced with a new SQL version. 
This database has proved to be a goldmine of information and has in large part been 
responsible for the plethora of publications which constitute this thesis. The vast majority 
of the statistical analysis for these papers has been done by myself. This was based on 
attending a number of statistical training courses over the years and becoming familiar 
with Statview – a user friendly statistics package 
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The chapters of this thesis reflect the differing emphasis of the publications over the past 
25 years, all of which have been designed with one aim: to improve outcomes for 
patients with musculoskeletal tumours.  
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Towards earlier diagnosis 
Sarcomas are rare, representing just 1% of all malignancy. The clinical features of both 
bone and soft tissue sarcomas are subtle and delays in diagnosis are common. In my first 
few years in oncology it soon became apparent that there was a very low level of 
recognition of these tumours and analysis of all new patients referred over one year 
confirmed this. The average time to diagnosis of patients with osteosarcoma was 13 
weeks but for Ewing’s sarcoma was 47 weeks. Whilst one third of this was due to patient 
delay before they had seen a doctor, approximately 2/3 was after they had consulted a 
doctor. Our article highlighting this was rejected as it was felt ‘to show doctors in too 
poor a light’, but we were instead invited to write an editorial on the subject.(1)  
Subsequent reviews of delays in diagnosis showed little change. This became a national 
issue in 1999 and I was invited to lead a group defining the diagnostic criteria for patients 
with possible bone and soft tissue sarcomas. This was very apposite as Charles Johnson (a 
medical student) and I had just completed an analysis of what were the worrying 
symptoms for patients with soft tissue sarcomas (STS).(2)  We used the sum weights of 
evidence method to demonstrate how the presence of four features led to an increasing 
likelihood of malignancy.  The findings of this study were subsequently directly adopted in 
both the 2000 Publication and the subsequent Guidance issued by NICE in 2005.(NICE 
Guidance. Referral Guidelines for Suspected Cancer. Available from: 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents
/digitalasset/dh_4014421.pdf/  [Accessed 14th November 2010] and  NICE Guidance. 
Referral Guidelines for Suspected Cancer 2005. Available from: 
http://www.nice.org.uk/nicemedia/live/10968/29816/29816.pdf [Accessed 14th 
November 2010]. 
Despite this there has been very little change in the time to diagnosis and this has led to a 
further editorial in 2010.(3)  Specific features that lead to delay have been highlighted for 
both sacral chordomas,(4)  and synovial sarcoma in children.(5)  Research by Smith and 
Johnson (medical students at the time) confirmed the long delays in patients with STS(6) 
showing that it was mostly doctor delay rather than patient delay, with referrals often 
being sent to the wrong place.  Subsequent initiatives such as the ‘two week wait’ were 
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anticipated to speed up the referral process but Taylor (again a medical student) found 
this was not the case.(7)  Over the years many patients have been referred to us with 
lumps ‘the size of grapefruits  or plums, or oranges ...’  We did a light hearted look at this 
in 2003, demonstrating that orthopaedic surgeons have no idea how big fruit really is and 
we found that they had a much better idea about how big inanimate objects were – with 
the best concordance being with the size of a golf ball! (8)  This size however (42mm) fits 
very neatly with the recommended size for early referral.  A further plea for earlier 
diagnosis was made in my Hunterian lecture “Improving outcomes for patients with 
sarcomas”.(9)  This suggested that a golf ball should be used as an ideal size to detect 
possible soft tissue sarcomas. 
The significance of delays in diagnosis was investigated for soft tissue sarcomas by 
Saithna, demonstrating that long duration of symptoms was correlated with lower grade, 
slower growing tumours – and thus with better prognosis.(10)  
In 1993 we became aware of problems with the histopathological reporting of cases in 
our unit. An independent enquiry identified that there had been 87 errors in reporting of 
1996 cases (4.4%). Some cases had been over-reported and some under-reported. Some 
patients had therefore had excessive treatment. The error rate was considered 
unacceptable even though the error rate was lower than any previously reported for 
bone and soft tissue pathology.(11)  Partly as a response to this, quality assurance was 
introduced and the mandate for double reporting of all malignancies. 
Staging of patients is important to assess the extent of their disease and Christie-Large 
showed the whilst CT will pick up most metastases it was only needed for large, deep high 
grade STS if the CXR was normal.(12)  The radiology of important differential diagnoses of 
bone tumours such as stress fractures has been clarified in several publications. (13-16) 
Patton showed that primary bone sarcomas can arise in patients with previous other 
malignancy either because of association with that malignancy, treatment of it or 
independently.(17) 
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Basic Science 
Collaboration is essential for fruitful scientific work and for a very clinically based 
orthopaedic surgeon (RJG) this is essential for any productive work in this area. The two 
units with whom we have had the greatest collaboration are the Royal Marsden Hospital 
in London and Mount Sinaii Hospital in Toronto.  These collaborations have resulted in a 
number of highly respected publications. The one with the highest citation index (275 
citations) was one identifying the responsible gene for synovial sarcoma in 2002.(18) 
Further work on synovial sarcoma and other soft tissue sarcomas was also produced.(19-
23)  The work with the team in Toronto was restricted by the terms of the Human Tissue 
Act which prevented further exchange of tissues for analysis but by then two useful 
studies had shown the lack of value of both the TP53 mutation and the MDR1 gene in 
predicting outcome for osteosarcoma. (24, 25) 
We have been able to carry out a number of limited studies in Birmingham.  Foukas 
showed that MMP-9 levels may be a prognostic indicator for osteosarcoma, Mangham 
showed that RT-PCR could be applied to both decalcified and non-decalcified paraffin 
sections to detect translocations diagnostic of Ewing’s sarcoma whilst Abudu showed that 
overexpression of p53 in Ewing’s sarcoma  was an independent poor prognostic factor. 
(26-28). Dalal showed that VEGF may be the single most important regulator of 
angiogenesis in Ewing’s sarcoma and could be a target for future therapeutic 
interventions.(29) 
Karpinski and I investigated the bone and  serum levels of a (then) new antibiotic- 
Augmentin. We showed that there was differential absorption of the two components 
(clavulanic acid and ampicillin) into bone and thus recommended that it should not be 
used for  prophylaxis in bone operations.(30) 
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Benign tumours 
Benign tumours considerably outnumber malignant ones but sometimes they present 
equally challenging management problems, particularly if they arise in children where the 
effects of a progressive lesion can lead to lifelong disability. 
Over the past 25 years our unit has continued a policy of largely conservative 
management  of benign tumours, using detailed curettage for those requiring it. 
Chondroblastomas are nowadays treated by radiofrequency ablation but any results from 
that would need to be compared with the gold standard of detailed curettage as shown 
by our paper of  2005 detailing a 13% risk of local recurrence, all of which arose within 18 
months.(31)  Not all chondroblastomas are that easy to treat and we described in more 
detail how to access chondroblastomas of the femoral epiphysis (32) and the very 
unusual circumstance of an apparently benign chondroblastoma which recurred 
aggressively and metastasised.(33)  
Giant cell tumours are one of the more aggressive ‘benign’ tumours with a high risk of 
local recurrence and occasional metastasis. Our unit policy of detailed  curettage without 
adjuvant resulted in a 19% risk of local recurrence.(34)  In the sacrum however treatment 
is far more difficult and a suggested algorithm has been produced based on our units 
experience.(35)  The distal radius is another site where treatment is difficult as is shown 
by Khan’s paper.(36) 
Curetting out a benign bone tumour leaves a defect in bone. Many people fill this with a 
variety of bone grafts or bone substitutes, most of which are expensive and which have 
never been shown to be effective, let alone cost effective. We analysed the size of defects 
left after curettage and identified 60ml as being the critical volume where filling the 
defect was required to avoid the risk of bone collapse.(37, 38)  In the proximal femur 
however structural support is often needed and a fibula strut graft is cheap and 
effective.(39)  Jeys showed that if more than 54% of the bone is destroyed then the risk of 
fracture increased in the distal femur.(40) 
Benign soft tissue tumours excite less interest but can still present challenges in diagnosis 
as in the case of one leiomyoma around the elbow. (41) 
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Primary Malignant Bone Tumours 
There are three main primary bone tumours with an annual incidence in the UK of about 
9/million population.  Since the database was established we have treated over 3327 of 
these patients, with an experience of 1527 osteosarcomas, 861 chondrosarcomas and 
682 Ewing’s patients. Several overviews of treatment for these have been published in 
prestigious journals.(42, 43) 
Osteosarcoma is the most common primary bone tumour. Low grade varieties such as 
parosteal osteosarcoma do not require chemotherapy but there remains uncertainty as 
to whether periosteal osteosarcoma requires this. Neither our own study nor a 
collaborative study with the members of the European Musculo-Skeletal Oncology Society 
(EMSOS) was able to answer this.(44, 45)  In high grade osteosarcoma there have been 
sequential chemotherapy trials in the UK over the past 30 years during which time there 
has been a disappointingly small change in overall survival (stuck at 53% at 5 yrs for the 
past 20 years or so). (46, 47)   Partly as a result of these disappointing outcomes I 
arranged for two medical students  (Ford and Saithna) to visit the Rizzoli Institute in 
Bologna to do a matched comparison of outcomes. Their results showed a significantly 
worse outcome in UK patients and presented a furore when presented at an International 
meeting, but this was in part responsible for a change in chemotherapy in the UK to a 
multiagent regime which appears to be improving outcomes.(48)  Bramer showed that 
change in alkaline phosphatase levels may   allow risk stratification for osteosarcoma.(49)  
Bramer and Pakos in separate studies have confirmed a wide range of  prognostic 
indicators for osteosarcoma.(50, 51)  Jeys showed that one of the most unexpected of 
these was the observation that patients with infected prostheses used for limb salvage 
had an increased survival,(52) an observation that fits with current osteosarcoma trials of 
immune modulators and with observations dating back to Coley’s toxins in the 1890s.  
One of the more dificult challenges clinicians face in managing osteosarcoma is what 
should be done with a patient with a pathological fracture. This question was originally 
addressed by Abudu in 1996 and later by Bramer (53, 54) both of whom showed that 
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fractures did not affect outcome per se but although there was a higher rate of 
amputation, limb salvage was safe if clear margins could be achieved.  Local recurrence in 
osteosarcoma is a feared outcome but is usually an indicator of aggressive and non 
responsive disease.(55)(56)  Outcomes following recurrence have also more recently been 
reviewed by Gelderblom combining data from three large osteosarcoma studies which 
our patients participated in, showing that outcome following local recurrence alone is not 
as bad as it is for metastases.(57)   
16% of osteosarcomas arise over the age of 40 and until a few years ago these patients 
were excluded from chemotherapy trials. Another combined paper from EMSOS showed 
that they did only marginally worse than younger patients when treated in a like 
manner.(58) We have shown that outcomes for  patients with pelvic osteosarcomas (59) 
and Paget’s osteosarcoma, (60) are worse, although fortunately Paget’s osteosarcoma 
appears to be becoming rarer.(61)  Kalra found that patients with radiation induced 
sarcomas also tended to do worse largely because of the awkward sites these tumours 
arose.(62) A most unusual case where tumour appears to have migrated to a site of 
increased vascularity following resection of an osteosarcoma was reported by Dias.(63) 
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Chondrosarcomas may arise de novo or arise in patients with solitary or multiple 
osteochondromas. They tend to be slow growing and frequently arise in the pelvis. They 
do not respond to chemotherapy or radiotherapy and surgical excision with clear margins 
gives the best prospect of cure. Our experience of treating chondrosarcoma is one of the 
largest in the world and confirms the effect of grade on survival and margins on local 
recurrence.(64)  A less aggressive tumour is clear cell chondrosarcoma  but this also 
requires recognition and treatment  with wide excision.(65)  A most unusual case where 
the tumour was possibly ‘reactivated’ after 21 years by revision hip surgery indicated the 
possible role of growth factors in facilitating tumour growth.(66) Of all the types of 
chondrosarcoma, the dedifferentiated type carries the worst prognosis and this was 
confirmed not only by our own experience but by the pooled results of a large 
consortium, the members of EMSOS. (67, 68)  Srikanth described the case of clear cell 
chondrosarcoma arising in association with Niemann-Pick disease.(69) 
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Ewing’s sarcoma on the other hand responds well to both chemotherapy and 
radiotherapy but there is increasing evidence that surgery is essential to optimise local 
control. (70) Our unit has been involved in sequential trials of chemotherapy for this 
disease and RJG has been the surgical co-ordinator for these trials since 1990.(71, 72)  
Ewing’s sarcoma can present in unusual ways (73) and a high level of awareness is needed 
to consider it as a possible diagnosis.  As long ago as 1999 Abudu showed a clear 
correlation between change in tumour size and histological response to chemotherapy, 
which helps allow planning of operative intervention.(74) 
 
 
Spindle cell sarcomas of bone comprise a rare group of bone tumours which are treated 
much like osteosarcoma with similar outcomes.(75)  We identified a previously 
unreported association of Neurofibromatosis Type 1 with an increased risk of bone 
tumours.(76) 
Although not a primary bone tumour, lymphomas of bone frequently present in a similar 
manner and have a better prognosis than bone sarcomas.(77) 
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Soft Tissue Sarcomas 
Soft tissue sarcomas (STS) are far more common than bone tumours. When I qualified 
they were very poorly recognised, were often diagnosed late and were usually treated 
with amputation.  Improvements in staging, surgery and adjuvant treatment have 
improved outcomes but up until the last 10 years most STS were still treated outside a 
specialist centre with worse outcomes.(78)  STS can present in varied ways (79, 80) but 
most are large by the time of presentation. Concern over our high rate of complications 
with adductor compartment STS led me to arrange for two students (Pradhan and 
Cheung) to visit two North American centres to do a comparison study of outcomes. 
Survival at all three centres was similar but aggressive local therapy improved local 
control significantly.(81)  This was not so apparent when a comparison was done of STS in 
the hand. (82) Aldlyami showed that Triton tumours are rare but behave aggressively (83) 
whilst Sommerville confirmed the satisfactory outcomes for  low grade liposarcomas (aka 
atypical lipomas) treated by marginal excision alone.(84)   
Inadvertent excision of a lump which turns out to be a sarcoma (the “whoops”  
procedure) is still unfortunately not uncommon and Chandrasekar’s paper showed that 
following re-excision residual tumour was found in 66% of cases and that local recurrence 
was related to grade of the tumour and margins of re-excision.(85)  Ferguson showed that 
local recurrence was of a higher grade in 20% of cases but this not predict a worse 
outcome.(86) Technical tips on resecting various soft tissue tumours have included how 
to resect a dumb bell tumour of the pelvis,(87)  an intravascular leiomyoma (88) and a 
chest wall sarcoma in a patient with aortic stenosis.(89) 
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Amputations. 
Approximately 15% of patients with bone or soft tissue sarcomas will need an amputation 
at some stage. The majority  will have a primary amputation as a result of the extent of 
their tumour but some will need it following a complication of the original treatment such 
as a local recurrence or an infection.  The higher in the limb the more devastating the 
amputation will be and also the likelihood that the reason the amputation was required  
was because the tumour was that much larger. Arguably the most mutilating of all 
amputations is the hindquarter amputation, where not only the leg but also part of the 
pelvis is removed. We reviewed our experience of 34 of these amputations in 1996, 
finding that when the amputation was done with curative intent there was a 85% survival 
at five years.(90)  Disarticulation of the hip stays outside the pelvic cavity but functionally 
is almost as debilitating as hindquarter amputation. It is mainly needed for large primary 
or recurrent tumours of the thigh.(91)  Outcomes are worse than those of hindquarter 
(only 32% survival at 5 yrs even for those done with curative intent) and this is probably a 
reflection of the fact that more hindquarter amputations are done for low grade 
chondrosarcomas. (10% of those having disarticulation compared with 32% for 
hindquarter). Following high amputation extra strain is placed on the contralateral limb 
and one of our surviving patients developed severe osteoarthritis of the remaining hip 
requiring a challenging hip replacement.(92) 
In the upper limb forequarter amputation has the same fearful reputation, only being 
required for massive inoperable tumours of the shoulder girdle. We found a 30.2% 
survival at five years for those done with curative intent.(93) 
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Endoprosthetic Replacement 
Joint replacements have been used since 1940 for arthritis and it was a logical step to use 
them for tumours. As the technology of joint replacement became more sophisticated so 
did the ambition of orthopaedic oncology surgeons to replace even larger parts of bones 
affected by tumours. In Birmingham this work was pioneered by Rodney Sneath who had 
learnt of the possibilities for endoprostheses to replace large segments of bone while 
working at Stanmore. 
On my arrival at the Royal Orthopaedic Hospital I was amazed to find that most surgeons 
were still doing knee replacements with an old fashioned hinged knee, the Stanmore 
knee.  It soon became apparent that the results, even in the medium term were very 
poor.  Karpinski and I obtained permission from the Consultant body to review outcomes 
and we reported on this in 1984.(94)  This paper was a landmark paper for two reasons. 
Firstly, it used the recently described actuarial survival to estimate failure rates (all the 
calculations were done using a calculator and the graphs were then drawn by hand) and 
secondly because it was the first paper to define three different endpoints for failure of 
an arthroplasty – removal of the prosthesis, the onset of pain or finally the onset of some 
other complication which detracted from the expected function. The failure rates using 
these three different criteria were 15%, 23% and 30% respectively at 5 years.  As a direct 
result of this paper the hospital changed to using more sophisticated knee replacements. 
A follow on paper also showed that using this knee for revisions resulted in only a 23% 
success rate.(95) 
This work however acted as a catalyst for subsequent reviews of the whole spectrum of 
endoprosthetic replacements which were by now increasingly being used in limb salvage 
surgery for bone tumours. Interestingly the most common implant – to replace the distal 
femur, was initially based on the very same Stanmore knee replacement which had such a 
high failure rate when used for arthritis. The paper by Roberts in 1991 showed a 28% 
failure rate at 5 years(96) whilst using the same prosthesis for proximal tibial 
replacements showed a 40% failure rate at 5 years.(97) This paper however also showed 
early improved results with the use of a rotating hinge type of implant and this has been 
confirmed by subsequent analysis. It also showed the value of the gastrocnemius muscle 
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flap in reducing infection rates. The main cause of failure of the early implants was 
aseptic loosening and Unwin demonstrated this in his paper of 1996.(98)  Myers showed 
that the change of implant to a rotating hinge and the use of hydroxyapatite collars at the 
bone/prosthesis interface has been responsible for a dramatic  improvement from a 35% 
rate of aseptic loosening to 0% at ten years in the distal femur and similar in the proximal 
tibia.(99, 100)  
Although prostheses are expensive and do fail, they are still very cost effective compared 
to the costs of an amputation with the need for lifelong provision of artificial limbs, an 
important point to consider for health care economists.(101) 
Apart from the knee, other sites where tumours commonly arise include the hip, pelvis 
and humerus and papers have reviewed our experience at all these sites. The proximal 
femur replacements do little worse than hip replacements in patients of the same age 
(102) and are especially useful for metastatic disease where a modular system is now 
available.(103) Proximal humeral replacements have the lowest complication rate of all 
the implants used although they allow only limited function at the shoulder and are 
realistically only spacers.(104)  The first patient to ever have a tumour prosthesis in 
Birmingham, in 1970, is now 91 years old and had her distal humerus prosthesis revised 
for loosening after 31 years. Endoprostheses of the distal humerus do surprisingly well 
considering the forces put upon the joint,(105) but in the distal tibia Abudu showed that 
the failure rate is very high and better function is usually achieved with a below knee 
amputation.(106) 
One of the main advantages of a diaphyseal prosthesis is that it allows immediate weight 
bearing but may fail in the longer term.(107, 108)  Replacing the entire bone is more 
challenging but may be needed for extensive tumours or revision procedures.(109, 110) 
Pelvic replacements are technically some of the most challenging surgical reconstructions 
and have a high complication rate which does not seem to have improved much with 
time.(111, 112) 
Unfortunately, inserting these large prostheses does not come without complications. 
The main continuing risk has been infection and the incidence of this is significantly higher 
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than in patients with conventional joint replacements. Abudu showed that if a superficial 
infection persists for more than 6 weeks it will almost certainly lead to a deep 
infection.(113)  Philips reviewed all deep infections in 10,735 primary arthroplasties  
carried out at our hospital over a 18 year period  and found a deep infection rate of 0.57% 
for hip and 0.86% for knee replacements. (114) Jeys found an 11% infection rate for 
patients with endoprostheses  over the same time period, also showing that pelvic, tibial 
and extendable prostheses were at greatest risk as were patient who had 
radiotherapy.(115) Dramis concluded that culture of Propionibacterium remained of 
uncertain significance. (116) Jeys showed that infection and local recurrence were the 
main reasons a secondary amputation was required after endoprosthetic replacement. 
(117, 118)  Management of infection has not changed much over the past 20 years with 
two stage revision remaining the best  way of resolving the problem.(119) Although 
radiotherapy may prevent tumour recurrence it dramatically increases the risks of failure 
around a prosthesis.(120)  
In children, our unit pioneered the use of extendible replacements, with the first one 
being done in 1982 in a patient who remains alive and well 29 years later. Early work 
concentrated on the concept of inserting an uncemented prosthesis across the growth 
plate opposed to the resected tumour (121) and subsequent review of this by Cool 
confirmed that growth continued despite the damage done to the growth plate.(122, 
123)  Early lengthenings were done ‘open’ with a distraction device and we measured the 
forces required to lengthen the soft tissues around the prostheses.(124) These results 
helped plan future lengthening devices and in particular the non invasive lengthening 
device where the lengthening is done using a motor. Results of extendible replacements 
have been reported for the distal femur(125), proximal femur (126), total femur (127), 
proximal tibia (128)and humerus.(129)  van Kampen showed that carrying out a hip 
replacement for tumour in an immature child is fraught with problems, especially 
subluxation, which have yet to be fully resolved.(130) 
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Other Surgery 
Other options for surgical reconstruction including biological solutions or rotationplasty 
should not be forgotten.(42, 43, 131)  Although fibula grafts in isolation are useful they 
are slow to heal and consolidate.(132)  In 1995 I began to use the technique of 
extracorporeal irradiation and reimplantation of bone tumours for selected cases. This is 
really most useful for unusual sites where there is no other good reconstruction available 
such as the pelvis (P1,2 resections), scapula, (133) mid tibia and in one case a metacarpal 
in a concert pianist!(134)    
Other inventive techniques have been developed in our unit to solve particular problems: 
the use of a prosthesis cemented over an existing one following a periprosthetic fracture 
being one neat solution described by Tillman.(135)  The use of an ‘ice cream cone’ 
prosthesis to reconstruct the pelvis also helps resolve the problem of the ‘missing hip 
joint’.(136)  Prostheses have also been used to resect bones affected by hydatid disease. 
(137) 
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Metastases 
Metastatic disease is usually incurable but effective palliation may often involve surgery. 
Chan and Baloch showed that resecting solitary metastases for renal cell carcinoma can 
provide prolonged palliation and occasionally cure.(138, 139)  The most common site for 
osseous metastases is in the proximal femur and the advantages of a modular system to 
allow early surgery and mobilisation for these patients has been demonstrated by 
Chandrasekar.(140)  Reconstructing pelvic defects using a modified Harrington technique 
has also met with considerable success in our hands as described by Tillman.(141)   Abed 
showed that soft tissue lumps which turn out to be metastases are uncommon but 
present in a  near identical way to soft tissue sarcomas – except that they are usually 
painful.(142) 
  
18 
 
Follow Up 
The aim of follow up is to reassure patients and detect problems at a stage when (in 
theory) they can be dealt with more easily. There is remarkably little evidence about the 
value of this for sarcomas. Cool showed that most local recurrences are detected by the 
patient themselves(143) and Gerrand showed the wide variation in follow up regimes 
used around the country.(144)  This topic is currently being investigated in collaboration 
with the University of Birmingham through a large grant from RFPB for the SOFI study. 
(Sarcoma Optimum Follow up Investigation).  Hauben showed that late relapse in 
osteosarcoma was not related to any clear histological factor.(145) 
Guidelines 
Guidelines on management are best achieved on a background of evidence supported by 
consensus. The British Sarcoma Group (of which RJG is the founder and secretary) has 
produced these  for both bone and soft tissue sarcomas.(146, 147) 
 
Quality of life (QoL) 
A fruitful association with Eiser produced a number of papers showing how difficult it is to 
measure QoL in children with bone tumours and how it is often the child’s ‘coping ability’ 
that best determines their perceived QoL.(148-153)   It also showed that children have 
better function following limb salvage but those who undergo secondary amputation 
following failed limb salvage adapt well to this.(154) 
 
 
 
 
 
 
19 
 
Conclusion 
Musculoskeletal oncology has emerged as a specialty in its own right since the 1980s. This 
is thanks to huge advances in imaging, surgical technique, chemotherapy and methods of 
limb reconstruction. It has been a privilege to be a part of this ‘revolution’. It has resulted 
in improved outcomes for patients both in terms of diagnosis, survival, limb salvage and 
quality of life.  The papers quoted in this thesis have highlighted many of the factors 
which have led to these improvements and demonstrated the author’s contributions to 
this subject over the past 30 years. The problems identified by this review will point the 
direction for the next generation of researchers. Already a list of 80 potential avenues for 
further investigation has been produced by the author.  
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